PPAR-gamma Agonists Induce Defensin Expression for Gut Barrier Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis lack effective curative therapeutic molecules, and impaired expression of enteric defensins contributes to the development of these chronic inflammatory disorders by compromising the epithelial barrier against pathogens.

Innovation Solution

PPAR-gamma agonists stimulate the expression of enteric defensins in the gut by activating PPAR receptors, enhancing the body's defense mechanisms against microbial infections and inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If conventional anti-inflammatory and immunosuppressive agents are used to treat IBD, then inflammation is suppressed, but the epithelial barrier function and antimicrobial defense are compromised

Engineering Contradiction:

ImproveinflammationVSAvoidepithelial barrier function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent converts the harmful effect of suppressed defensin expression into a beneficial therapeutic effect by using PPAR-gamma agonists to stimulate defensin production. The agonists activate PPAR-gamma receptors in epithelial cells, which then upregulate defensin expression through transcriptional activation, thereby restoring the antimicrobial barrier function that was compromised by conventional therapy

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the physiological parameter of defensin expression levels by introducing PPAR-gamma agonists. These agonists bind to PPAR-gamma receptors and trigger a signaling cascade that increases defensin gene transcription and protein expression, thereby altering the immune defense parameter from a suppressed state to an activated state

Inventive Principle:

Principle #35Parameter changes

2Reliability

If PPAR-gamma agonists are used to stimulate defensin production, then antimicrobial protection is enhanced, but the complexity of therapeutic management increases

Engineering Contradiction:

Improveantimicrobial protectionVSAvoidtherapeutic management

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent demonstrates that PPAR-gamma agonists have multiple therapeutic functions: they stimulate defensin production for antimicrobial protection, reduce inflammation through PPAR-gamma mediated pathways, and enhance epithelial barrier function. This multi-functionality allows a single agent to address multiple aspects of IBD pathophysiology simultaneously, thereby reducing overall therapeutic complexity

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentEP2131829B1PPAR-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants

Publication Date: 2012.04.18 NOGRA PHARMA LTD

Figure 1~4
Figure 5
Figure 6A~6B

AI summary

Rosiglitazone, 5-ASA or structurally analogous Compounds according to the general formula (I): or Compounds according to the general formula (Ia): For the induction of CAMP expression in tissues having PPAR-gamma receptors. Such tissues include epithelia or mucosae tissue having PPAR-gamma receptors and of particular interest ?s CAMP expression in the gut